INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Observational study / 2011

Direct-to-consumer genomewide risk profiling did not result in measurable short-term changes in dietary fat intake, exercise, or anxiety.

Researchers examined the psychological, behavioral, and clinical effects of risk scanning using the commercially available Navigenics Health Compass test. Among 2,037 subjects who completed follow-up at a mean of 5.6±2.4 months, primary analyses showed no significant differences between baseline and follow-up in anxiety symptoms (P=0.80), dietary fat intake (P=0.89), or exercise behavior (P=0.61). Test-related distress positively correlated with average estimated lifetime risk across conditions (β=0.117, P<0.001), though 90.3% of respondents had scores indicating no distress. There was also no significant increase in the rate of screening test use.

Shows an association, not proof of cause and effect.

Study type
Prospective cohort study
Who was studied
2,037 subjects who completed follow-up out of 3,639 enrolled from health and technology companies
What was measured
Changes in anxiety symptoms, dietary fat intake, exercise behavior, test-related distress, and use of health-screening tests

THE PAPER

Effect of direct-to-consumer genomewide profiling to assess disease risk.

Bloss CS, Schork NJ, Topol EJ. N Engl J Med, 2011.

PubMed 21226570 ↗DOI 10.1056/nejmoa1011893 ↗

Nutrients & adequacyOther health

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.